|Bid||0.17 x 1400|
|Ask||8.22 x 1200|
|Day's Range||6.74 - 7.15|
|52 Week Range||5.66 - 30.00|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.60|
You may be surprised to hear this, but a large amount of short interest in a stock could actually be a buy signal.What is short selling a stock? It's selling a stock that you don't own with the intention of buying it back at a lower price in the future, usually using options. And short interest is the number of shares that are sold short that haven't been bought back yet. It is usually expressed as a ratio of shares that are short to the total number of outstanding shares.The short interest can also be expressed as "Days to Cover." This is the number of short shares divided by the average daily trading volume. In other words, it is the number of days that it would take for all the short shares to be bought back.InvestorPlace - Stock Market News, Stock Advice & Trading TipsI should note, this number should be considered understated, because it assumes purchasing 100% of the volume. This would be impossible in normal markets. It would be more realistic to assume that short sellers could only buy about 10%-15% of the average daily volume with adversely affecting the price. * 7 Safe Stocks to Buy for Anxious Investors You should pay attention to this because really high short-interest could be a bullish signal. This is because these shares need to be bought back. These short-sellers will all eventually become buyers! Trupanion (TRUP)Trupanion (NASDAQ:TRUP) provides medical insurance for cats and dogs. It has a subscription business and also offers insurance to companies that can provide it as a benefit to their employees.There are about 11.2 million shares currently short. This is 38% of the outstanding float. The average daily volume recently is about 145,000. That means the days to cover would be about 77. And remember, that assumes buying 100% of the volume.It would be more realistic to assume that one could only trade about 10% of the volume without adversely affecting the price. That means it could take years for the shorts to cover all of their positions!Wall Street seems to disagree with the shorts. Six firms follow it and the all have buy ratings on it. The average price target is $40. Accelerate Diagnostics (AXDX)Accelerate Diagnostics (NASDAQ:AXDX) engages in developing and selling instruments that are used to fight infectious pathogens.There are 14.1 million shares currently short in this company. That is 52% of the float. That means that there are guaranteed buyers for about half of the company's stock! Assuming that they buy 10% of the average daily volume, it would take about two years to cover it. * 7 Stocks to Buy for Over 20% Upside Potential All four of the analysts who cover this have a buy rating on it according to Yahoo Finance. OptiNose (OPTN)OptiNose (NASDAQ:OPTN) develops and sells products that are for the treatment of ear, nose, throat and allergy illnesses.The short-interest is 7.9 million, or about 49% of the float. Over the past year, the price of the stock has fallen from $30 to current levels around $9.Wall Street doesn't feel as bad about this company's prospects as the short sellers do. It likes this stock. All four analysts that follow it have it rated as a buy and the average target price is $25. That is about three times higher then where it is currently trading. Energy Recovery (ERII)Energy Recovery (NASDAQ:ERII) develops and sells products that are for industrial fluid flow application. Their customers include oil and gas companies.5.5 million shares are currently short. That is about 14% of the float. It isn't as much as the other companies, but it is still pretty high. It only trades about 112,000 on a typical day, so that would give a days to cover number of about 50. Using our estimate of being able to only acquire about 10%-15% of the volume that trades with adversely affecting the price, it would take over a year to cover. * 7 High-Yield REITs to Buy (Even When the Market Tanks) There are six buys on this company. The average target price is about $16, which is about 60% above current prices. Seres Therapeutics (MCRB)Seres Therapeutics (NASDAQ:MCRB) creates medicines "using live bacteria to treat diseases that result from functional deficiencies in the microbiome."The share price fell dramatically over the past month. The current short interest is 5.3 million of the float. That is about 25%. With an average daily volume of about 111,000, the days to cover is 48.This company is followed by nine Wall Street firms. Seven have it rated as a buy and the other two have it as a hold. The average target price is $11 and it is currently trading below $5. Theravance Biopharma (TBPH)Theravance Biopharma (NASDAQ:TBPH) is a biopharmaceutical company. It focuses and the research, development and commercialization of small molecule medicines.The short-interest ratio here is "only" 15%, or 6.3 million shares. The stock only trades about 154,000 shares on a typical day, so that is 41 days to cover.Remember, it is safe to assume that they can buy about 10% of the volume without adversely affecting the price. * 6 Chinese Stocks That Could Pop On a Trade Deal Seven firms follow this company. Four of them have it rated a buy and three have it as a sell. The average target price is just over $38 per share.As of this writing, Mark Putrino did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Safe Stocks to Buy for Anxious Investors * 4 Tech Stocks Looking Vulnerable * Should You Buy, Sell, Or Hold These 7 Hot IPO Stocks? Compare Brokers The post You Can Get Buy Signals From Short Selling appeared first on InvestorPlace.
OptiNose (OPTN) delivered earnings and revenue surprises of 1.41% and 2.99%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Yardley, Pennsylvania-based company said it had a loss of 70 cents. The specialty pharmaceutical company posted revenue of $4.5 million in the period. OptiNose shares have climbed ...
Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended March 31, 2019, and provided recent operational highlights. At the same time, the Company completed its transition from a contract sales force model to an internal sales force model.
OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. So shareholders might...
Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the first quarter 2019, before market open on Thursday, May 9, 2019. Members of the Company’s leadership team will host a conference call to discuss financial results and corporate updates, including its launch of XHANCE®. A simultaneous webcast of the call and presentation can be accessed by visiting the Investors section of Optinose’s website at www.optinose.com.
OptiNose In c (NASDAQ: OPTN ) has introduced a new and simplified co-pay assistance program that's led to good script performance, according to Cantor Fitzgerald. The ear, nose and throat drugmaker expects ...
Company reports fourth quarter and full year 2018 net XHANCE revenue of $3.0 million and $7.1 million XHANCE prescriptions increased 50 percent from Q3 to Q4 of 2018.
Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the fourth quarter 2018, before market open on Wednesday, March 6, 2019. Members of the Company’s leadership team will host a conference call to discuss financial results and corporate updates, including its launch of XHANCE®. A simultaneous webcast of the call and presentation can be accessed by visiting the Investors section of Optinose’s website at www.optinose.com.
Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the United States Patent and Trademark Office (USPTO) recently issued four patents covering XHANCE® (fluticasone propionate) nasal spray. “We are pleased to further strengthen our intellectual property portfolio with the addition of these patents.
YARDLEY, Pa., Feb. 15, 2019 -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today.
Inexia obtained certain rights that will enable it to use Optinose’s exhalation delivery system when developing potential therapies for neurological diseases.
Optinose (OPTN), a pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it has entered into a license agreement with Inexia whereby Inexia has obtained certain rights that will enable the use of Optinose’s Exhalation Delivery Systems (EDS) and other intellectual property in their effort to discover and develop novel therapies based on positive modulators of Orexin OX1 and OX2 for neurological diseases.
Investors are always looking for growth in small-cap stocks like OptiNose, Inc. (NASDAQ:OPTN), with a market cap of US$248m. However, an important fact which most ignore is: how financially healthy Read More...
Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stock hit 52-week high in Wednesday's session. Down In The Dumps (Biotech stocks hitting 52-week lows on Dec. ...
NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company received written notice from Avanir Pharmaceuticals, Inc. of its election to terminate the License Agreement to develop and commercialize ONZETRA® XSAIL® in the United States, Canada, and Mexico. Upon termination of the license agreement, Optinose may elect to continue to commercialize ONZETRA XSAIL itself or through a new licensee. “Optinose intends to evaluate its options with respect to the future of ONZETRA XSAIL,” stated CEO Peter Miller.
YARDLEY, Pa., Dec. 10, 2018 -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, announced.
Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present at the 2018 Prescriptions for Success Healthcare Conference on December 12, 2018, at 11:00 a.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay of the webcast will be available for 30 days following the conclusion of the event.
At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Third Point because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices. Out of thousands of stocks that hedge funds invest in, small-caps […]
OptiNose (OPTN) delivered earnings and revenue surprises of 10.29% and 21.15%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Yardley, Pennsylvania-based company said it had a loss of 61 cents per share. The specialty pharmaceutical company posted revenue of $1.9 million in the period. OptiNose shares have decreased 45 percent ...